Randomized Phase IIA Clinical Study of an Anti-\(\alpha_{\text{v}}\beta_{6}\) Monoclonal Antibody in Idiopathic Pulmonary Fibrosis

To the Editor:

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease with high mortality and limited treatment options (1). A potential therapeutic target is the inhibition of active TGF-\(\beta\) (transforming growth factor-\(\beta\)), a critical cytokine in the initiation and maintenance of fibrosis (2). In preclinical studies, partial inhibition of TGF-\(\beta\) using anti-\(\alpha_{\text{v}}\beta_{6}\) integrin antibodies was effective in blocking murine pulmonary fibrosis without exacerbating inflammation (3–6).

BG00011 (formerly STX-100) is a first-in-class, humanized anti-\(\alpha_{\text{v}}\beta_{6}\) IgG1 monoclonal antibody that blocks the binding of \(\alpha_{v}\beta_6\) to the latent form of TGF-\(\beta\), thereby inhibiting TGF-\(\beta\) activation. Animal studies showed that BAL cells act as biosensors of \(\alpha_{v}\beta_6\)-mediated TGF-\(\beta\) activation (7). pSMAD2, a key mediator of TGF-\(\beta\) activity (8) that correlates with lung fibrosis (9), was selected as an exploratory target biomarker.

We report the results of a phase IIA study that evaluated the safety and tolerability of multiple ascending doses of BG00011 in patients with IPF. The quantification of biomarkers of TGF-\(\beta\) activity in BAL cells was a secondary objective to evaluate biological activity; there were no efficacy objectives. Some of the results of these studies have been previously reported in the form of an abstract (7).

Methods
This randomized, double-blind, placebo-controlled, dose-escalation study (NCT01371305) was conducted from July 16, 2012, through March 31, 2017, at 17 sites in the United States. Patients with IPF with a predicted FVC \(\geq 50\%\) were randomized 3:1 to receive subcutaneous BG00011 (\(n = 31\)) or placebo (\(n = 10\)) once weekly for 8 weeks. Patients were enrolled into 5 dose cohorts (0.015–3.0 mg/kg, \(n = 8\) each) and followed for an additional 12 weeks. The study was approved by all relevant institutional review boards. Informed consent was obtained from all participants.

Safety evaluations included treatment-emergent adverse events (TEAEs), clinical and laboratory assessments, and pulmonary function testing (PFT). TEAEs of IPF exacerbation were diagnosed by the investigator on the basis of published criteria (10) and were not adjudicated.

BAL cells isolated via bronchoscopy at screening and up to Day 8 after dose were evaluated for changes in TGF-\(\beta\) activity biomarkers (pSMAD2 and seven prespecified genes: ALOX5, ETS1, FN1, OLR1, PAI-1, TGM2, and TREM1). An exposure–response relationship was evaluated on the basis of the BG00011 area under the concentration time curve at steady state (AUC\(_{\text{SS}}\)) and the percent change from baseline in pSMAD2/tSMAD2.

All analyses were descriptive and exploratory.

Results
Baseline characteristics were similar between the BG00011 and placebo groups (mean age, 69 vs. 72 years; mean percent predicted FVC, 75\% vs. 81\%). Thirty patients (23 BG00011 and 7 placebo) completed the study (8 doses and follow-up) (Table 1). The 3.0 mg/kg dose cohort was terminated because of the prespecified stopping criteria of a clinically significant decline in respiratory function in four of six patients at Week 16; only two patients in this cohort completed the study.

Safety
TEAEs were reported in 27/31 patients (87.1\%) who received at least one dose of BG00011 and 7/10 patients (70.0\%) who received placebo (Table 1); most were mild or moderate. IPF exacerbation occurred in two patients in the 1.0 mg/kg cohort and three in the 3.0 mg/kg cohort. Eight serious adverse events were reported in four (12.9\%) patients treated with BG00011, including one death.

At Week 16 (Day 8 of follow-up), one patient in the 1.0 mg/kg cohort, four patients in the 3.0 mg/kg cohort, and two patients in the placebo group had a clinically meaningful decline from baseline in PFT values (predefined as either total lung capacity \(\geq 8\%\), FEV\(_1\) \(\geq 12\%\), FVC \(\geq 12\%\), and/or diffusing capacity for carbon monoxide adjusted for hemoglobin \(\geq 15\%\)). Of the four patients in the 3.0 mg/kg cohort, one had a clinically significant decline in total lung capacity without change in spirometry and without symptoms, and three had a clinically significant decline in FVC (one after dosing had been stopped). No clinically meaningful changes in PFT were observed in the 0.015 mg/kg, 0.1 mg/kg, and 0.3 mg/kg dose cohorts.

Biomarkers of TGF-\(\beta\) Activity
A dose-dependent decrease from baseline to last dose in pSMAD2/tSMAD2 ratio was observed in the 0.1, 0.3, 1.0, and 3.0 mg/kg cohorts (mean percentage change of \(-3.33\%\), \(-39.82\%\), \(-63.74\%\), and \(-76.20\%\), respectively). A \(\geq 70\%\) reduction in pSMAD2 concentrations was observed in 1/5, 4/5, and 2/3 patients in the 0.3 mg/kg, 1.0 mg/kg, and 3.0 mg/kg cohorts, respectively. In the 3.0 mg/kg cohort, only three patients underwent BAL, and one did not have analyzable pSMAD2 data. ALOX5, FN1, OLR1, TGM2, and TREM1 also showed dose-dependent decreases in BAL cell expression.

Pharmacokinetics and Exposure–Response
The BG00011 half-life was approximately 6 days, and a steady state was reached after the fifth dose with minimal \((\sim 1.5\times)\) accumulation using weekly dosing. A dose–response was observed between the BG00011 AUC\(_{\text{SS}}\) after the last dose and the percent change from baseline in pSMAD2/tSMAD2, starting at the 0.3 and 1.0 mg/kg doses (Figure 1).

Discussion
In this small phase IIA study, once-weekly subcutaneous administration of BG00011, at doses less than 1.0 mg/kg, was generally well tolerated by patients with IPF. However, acute IPF exacerbation occurred among patients at higher doses of BG00011. Furthermore, the study met the predefined stopping criteria at the...
Table 1. Summary of Treatment-emergent Adverse Events

| n (%) | BG00011 Dose Cohort | Overall |
|-------|---------------------|---------|
|       | 0.015 mg/kg n=6    | 0.1 mg/kg n=6 | 0.3 mg/kg n=6 | 1.0 mg/kg n=7 | 3.0 mg/kg n=6 | BG00011 n=31 | Placebo n=10 |
|       | 0.7 mg/kg |  |  |  |  |
| Completed study (8 doses and follow-up) | 4 (66.7) | 6 (100) | 6 (100) | 5 (71.4) | 2 (33.3)* | 23 (74.2) | 7 (70.0) |
| Any TEAE | 6 (100) | 5 (83.3) | 6 (100) | 4 (57.1) | 6 (100) | 27 (87.1) | 7 (70.0) |
| TEAE occurring in ≥4 patients | | | | | | | |
| Cough | 1 (16.7) | 0 | 1 (16.7) | 1 (14.3) | 2 (33.3) | 5 (16.1) | 1 (10.0) |
| Dyspnea | 1 (16.7) | 2 (33.3) | 0 | 1 (14.3) | 1 (16.7) | 5 (16.1) | 1 (10.0) |
| IPF exacerbation | 0 | 0 | 0 | 2 (28.6) | 3 (50.0) | 5 (16.1) | 0 |
| Hypoxia | 2 (33.3) | 0 | 0 | 2 (28.6) | 0 | 4 (12.9) | 0 |
| Upper RTI | 2 (33.3) | 0 | 1 (16.7) | 0 | 1 (16.7) | 4 (12.9) | 1 (10.0) |
| Dizziness | 0 | 1 (16.7) | 1 (16.7) | 1 (14.3) | 1 (16.7) | 4 (12.9) | 1 (10.0) |
| Rash | 0 | 2 (33.3) | 2 (33.3) | 0 | 0 | 4 (12.9) | 0 |
| Serious TEAE | 1 (16.7)*† | 0 | 0 | 2 (28.6)† | 1 (16.7)§ | 4 (12.9) | 0 |

Definition of abbreviations: IPF = idiopathic pulmonary fibrosis; RTI = respiratory tract infection; TEAE = treatment-emergent adverse event.

Adverse events were coded using the Medical Dictionary for Regulatory Activities version 20.0. Safety was assessed in all patients who received at least one dose of the study drug.

*The 3.0 mg/kg dose cohort was terminated early because of a clinically significant decline in respiratory function at Week 16 in four of six patients.
†One patient experienced two serious TEAEs. A complete atrioventricular block was observed on Day 11, requiring pacemaker placement. The patient restarted treatment and completed dosing. On Day 105, during the follow-up period (approximately 49 days after dosing was completed), the patient experienced a serious adverse event of hypoxemia, which lasted for 2 days and resolved.
‡One patient had IPF exacerbation on Day 60. Lung transplantation was required, and the patient was ultimately withdrawn from the study. The second patient had type II second-degree atrioventricular block requiring pacemaker implantation, syncope, and jaw fracture on Day 26 and had an IPF exacerbation on Day 38 that resulted in death after 4 days.
§Respiratory failure after viral respiratory infection on Day 69, which lasted for 2 days and resolved.

Figure 1. Exposure–response analysis: relationship between BG00011 exposure and percent change from baseline in pSMAD2 expression. AUCss = area under the concentration time curve at a steady state; pSMAD2/tSMAD2 = ratio of phosphorylated SMAD2 to total SMAD2.
3.0 mg/kg dose, identifying a potential risk of decline in respiratory status with higher doses of BG00011.

The results suggest that targeting the αvβ6-integrin with BG00011 inhibits TGF-β activation and may interrupt fibrogenesis. BAL cell analysis showed an inhibitory effect of BG00011 on pSMAD2 expression, starting at the 0.3 mg/kg dose and achieving ≥70% reduction at 1.0 mg/kg, establishing proof of biological activity. The observed biological response of BG00011 resembled that seen in mice and primates (7).

To guide the selection of a safe and biologically active BG00011 dose for subsequent clinical trials, a pharmacodynamic exposure–response analysis was conducted on the basis of Week 8 AUC0-ss (Figure 1). A steep dose response was observed between BG00011 exposure and pSMAD2 inhibition up to the 1.0 mg/kg dose, at which point pSMAD2 was reduced by 70%, and efficacy plateaued. A flat dose of 36 μg (~0.7 mg/kg) was selected for the phase IIb study (NCT03573505) (11) to provide the optimal therapeutic dose for subsequent clinical trials, a pharmacodynamic activity. The observed biological response of BG00011 resembled that seen in mice and primates (7).

Given the small number of patients and the exploratory nature of this analysis, the results should be interpreted with caution. Larger studies are required to confirm the potential dose–response effect of BG00011 on TGF-β suppression and define clinical efficacy.

Author disclosures are available with the text of this article at www.atsjournals.org.

Acknowledgment: The authors would like to thank the study investigators, Daniel A. Culver, M.D., Mark J. Hamblin, M.D., Jeffrey A. Golden, M.D., Srinath Veeraraghavan, M.D., Richard I. Enelow, M.D., Lisa H. Lancaster, M.D., Hilary J. Goldberg, M.D., Leo C. Grims, M.D., and Ivan O. Rosas, M.D., as well as the patients who participated in this trial and their families, the study coordinators, study teams, and nurses. The authors also thank the members of the Data and Safety Monitoring Board, Kevin Brown, M.D. (National Jewish Health, Denver, Colorado), Fernando Martinez, M.D. (Weill Cornell Medical Center, New York, New York), and Barry Tumblin, Ph.D. (retired), as well as David Lynch, M.D. (National Jewish Health), for his review of the computed tomography images for idiopathic pulmonary fibrosis diagnosis and participation as an ad hoc member of the Data and Safety Monitoring Board. The authors were assisted in the preparation of the manuscript by Jean Turner, a professional medical writer with Parexel International (Waltham, Massachusetts). Writing support was funded by Biogen (Cambridge, Massachusetts).